Evidence map›Paper›PMID 29980333›Full record

Trial reportOphthalmology2018

Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.

Susan B Bressler, Wesley T Beaulieu, Adam R Glassman, Jeffrey G Gross, Michele Melia, Eric Chen, Michael R Pavlica, Lee M Jampol, Diabetic Retinopathy Clinical Research Network

Registry-linked trialOpen access · greenAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01489189 (Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy), which is not on this map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01489189 phase3completednot on this map

Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab With Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

TypeinterventionalSponsorJaeb Center for Health ResearchRan2012 to 2018Enrolled305ConditionsProliferative Diabetic RetinopathyArmsPrompt Panretinal Photocoagulation, 0.5-mg Ranibizumab, Deferred panretinal photocoagulation
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Diabetic retinopathy-recommendations for screening and treatment.Wiener medizinische Wochenschrift (1946) · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Susan B BresslerWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Wesley T BeaulieuJaeb Center for Health Research, Tampa, Florida. Electronic address: drcrstat8@jaeb.org.
Adam R GlassmanJaeb Center for Health Research, Tampa, Florida.
Jeffrey G GrossCarolina Retina Center PA, Columbia, South Carolina.
Michele MeliaJaeb Center for Health Research, Tampa, Florida.
Eric ChenRetina Consultants of Houston, Houston, Texas.
Michael R PavlicaFamily Eye Group, Lancaster, Pennsylvania.
Lee M JampolFeinberg School of Medicine, Northwestern University, Chicago, Illinois.
Diabetic Retinopathy Clinical Research Network
Jaeb Center for Health Research · USCarolina Retina Center · USJohns Hopkins University · USNorthwestern University · USRetina Consultants of Texas · US

Funding

DIABETIC RETINOPATHY CLINICAL RESEARCH NETWORK COORDINATING CENTERU10EY014231 · NEI · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI GLASSMAN, ADAM R · 2002 to 2018
$91.2M
DRCR Retina NetworkUG1EY014231 · NEI · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI Adam R Glassman, DANIEL F MARTIN · 2019 to 2026
$75.4M
Diabetic Retinopathy Clinical Research Network Chair GrantU10EY023207 · NEI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI JAMPOL, LEE M · 2014 to 2018
$1.8M
Diabetic Retinopathy Clinical Research Network Operations CenterU10EY018817 · NEI · JOHNS HOPKINS UNIVERSITY · PI BRESSLER, NEIL MICHAEL · 2009 to 2013
$769k
NEI NIH HHS U10 EY014231NEI NIH HHS U10 EY018817NEI NIH HHS U10 EY023207NEI NIH HHS UG1 EY014231
6 · The paper itself

Abstract

purposeTo identify baseline factors associated with change in visual acuity or development of vision-impairing central-involved diabetic macular edema (DME) over 2 years when treating proliferative diabetic retinopathy (PDR) with ranibizumab or panretinal photocoagulation (PRP).

designPost hoc analyses of randomized, multicenter clinical trial data.

participantsEyes completing the 2-year visit (n = 328) or without vision-impairing central-involved DME at baseline (n = 302) in Diabetic Retinopathy Clinical Research Network Protocol S.

methodsIntravitreous ranibizumab (0.5 mg/0.05 ml) or PRP.

main outcome measuresChange in visual acuity (area under the curve) and development of vision-impairing (20/32 or worse) central-involved DME over 2 years.

resultsAfter multivariable model selection with adjustment for baseline visual acuity and central subfield thickness, no factors were identified as associated with change in visual acuity or development of vision-impairing central-involved DME within the ranibizumab group. In the PRP group, worse change in visual acuity was more likely with higher hemoglobin A

conclusionsFor eyes managed with PRP, higher hemoglobin A

Indexed as

AgedAngiogenesis InhibitorsArterial PressureDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Diabetic RetinopathyFemaleGlycated HemoglobinHumansIntravitreal InjectionsLaser CoagulationMacular EdemaMaleMiddle AgedRanibizumabTomography, Optical CoherenceAngiogenesis InhibitorsGlycated Hemoglobinhemoglobin A1c protein, humanRanibizumabVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID29980333
PMCPMC6566865
OpenAlexW2809898434

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.